EUVIMED · CrossrefZeitschrift
Journal of Clinical Oncology
ISSN 0732-183X · American Society of Clinical Oncology (ASCO)
Neueste Artikel
Second Cancer Risk in Female Survivors of Hodgkin Lymphoma: A National Cohort Analysis Across Treatment Eras
Retraction: PIN1, Cholesterol Biosynthesis, and Clinical Outcomes in Urothelial Carcinoma (UC): A Propensity-Weighted Real-World Clinicogenomic Analysis
Patient-Level Evaluation of Optimal Margin Width for Lumpectomy in Ductal Carcinoma In Situ: An Analysis of Patients in the National Cancer Database Special Study
Headwinds in Breast Cancer Research: The Case for Pragmatic Radiotherapy De-escalation Studies
Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial
Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial
Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505)
To Be Loved
P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR –Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape
Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab
RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial
Financial Payments From Drug Manufacturers to Oncologists and Use of Guideline-Preferred Cancer Treatments
Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide
Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia's Landmark Tumor-Agnostic Immunotherapy Reimbursement
Reply to: Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab
Reply to: Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide
When Industry Payments to Oncologists Influence Cancer Care
Surgery and Tile-Based Radiation Therapy Versus Surgery and Stereotactic Radiation for Newly Diagnosed Brain Metastases: A Randomized, Open-Label, Phase III Trial
Bridging the Gap: From Molecular Residual Disease to Curative Opportunity: Circulating Tumor DNA–Guided Surveillance After Curative Resection for Stage I to III Colorectal Cancer
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline, Version 2026.1.2
Erratum: If Exercise Were a Pill, We'd All Prescribe It to Patients With Cancer. But It's Not
Treatment of Stage IB to III Nasopharyngeal Carcinoma: CSCO-ASCO Guideline Update
Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma: CSCO and ASCO Joint Guideline
Modeling Long-Term Progression-Free Survival in Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone
Image-Based Consensus Molecular Subtyping Refines Prognostication in Stage II/III Colorectal Cancer: A Retrospective Analysis of the SCOT Trial
Methylphenidate for Fatigue in Patients With Stable Hematologic Malignancies
Per- and Polyfluoroalkyl Substance Exposure and Breast Cancer Incidence in the Sister Study
Perfluoroalkyl Substances and Estrogen Receptor‑Negative Breast Cancer: Looking Beyond Traditional Risk Factors
Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53 , STAG2 , and CDKN2A Alterations
International Initiative on a Refined Staging System for Medullary Thyroid Cancer: A Multinational Multicenter Study
Jahrgänge
2026 · 2.0082025 · 8.8002024 · 8.1722023 · 8.1202022 · 7.4742021 · 6.4682020 · 7.8602019 · 7.5262018 · 8.2022017 · 7.8552016 · 7.9002015 · 7.4922014 · 7.5792013 · 7.0662012 · 7.4562011 · 6.9222010 · 5.9392009 · 5.3762008 · 5.5462007 · 5.3152006 · 4.9992005 · 5.1232004 · 4.4202003 · 9192002 · 7872001 · 6302000 · 5781999 · 5321998 · 5681997 · 4811996 · 4431995 · 4331994 · 4111993 · 3691992 · 3091991 · 3281990 · 3051989 · 2901988 · 2741987 · 319
EUVIMED